Experts: Federal, State Oversight Of 503B Compounding Falls Short

January 25, 2018 at 1:23 PM
Current oversight and regulation of the outsourcing compounding industry is insufficient and enforcement of the current guidelines is too lax, according to a recent white paper that came out of roundtable discussions with top compounding experts. The paper also paints a stark picture of compounders’ compliance with best practices and physician knowledge of when drugs they administer are compounded. The paper was published just shortly after FDA revealed its 2018 compounding policy priorities and just days before the House Energy...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.